← back to search

Tariq Jamal Siddiqi

Baylor University Medical Center · US
Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Heart Failure Treatment and Management, Diabetes Treatment and Management, Cardiovascular Function and Risk Factors, and Cardiac Valve Diseases and Treatments.
h-index
41
citations
52,848
works
164
NIH funding
primary concept
Medicine
email

Recent publications

Coordinated Expression of BMP10/ALK1/endoglin—Proteins that Drive Embryonic Cardiac and Vascular Morphogenesis—in Patients with Heart Failure: The EMPEROR Program
European Journal of Heart Failure 2025cited by 1position: middledoi
Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
Journal of the American College of Cardiology 2023cited by 130position: middledoi
Association of Electronic Cigarette Exposure on Cardiovascular Health: A Systematic Review and Meta-Analysis
Current Problems in Cardiology 2023cited by 43position: firstdoi
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories
Journal of the American College of Cardiology 2023cited by 40position: middledoi
Health Status Across Major Subgroups of Patients with Heart Failure and Preserved Ejection Fraction
European Journal of Heart Failure 2023cited by 24position: firstdoi
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial
European Heart Journal 2022cited by 211position: middledoi
Trends in Heart Failure–Related Mortality Among Older Adults in the United States From 1999-2019
JACC Heart Failure 2022cited by 132position: firstdoi
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
Circulation 2022cited by 55position: middledoi
Early benefit with empagliflozin in heart failure with preserved ejection fraction: <scp>insights from the EMPEROR‐Preserved trial</scp>
European Journal of Heart Failure 2022cited by 52position: middledoi
Outcomes with empagliflozin in heart failure with preserved ejection fraction using <scp>DELIVER</scp> ‐like endpoint definitions
European Journal of Heart Failure 2022cited by 19position: middledoi
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the <scp>DIAMOND</scp> trial
European Journal of Heart Failure 2021cited by 44position: middledoi
Is there a smoker’s paradox in COVID-19?
BMJ evidence-based medicine 2020cited by 154position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Javed Butler · Jackson College8 papers (2022–2025)Gerasimos Filippatos · German Centre for Cardiovascular Research7 papers (2021–2023)João Pedro Ferreira · Institut des Sciences et technologies pour une Economie Circulaire des énergies bas carbone6 papers (2022–2025)Stuart Pocock · London School of Hygiene & Tropical Medicine5 papers (2022–2023)Faı̈ez Zannad · Université de Caen Normandie5 papers (2022–2023)James L. Januzzi · Sentara Heart Hospital5 papers (2022–2025)Stefan D. Anker · Council for British Research in the Levant5 papers (2021–2025)Martina Brueckmann · University Hospital Heidelberg4 papers (2022–2023)Milton Packer · Baylor University Medical Center4 papers (2022–2023)Ileana L. Piña · Thomas Jefferson University4 papers (2021–2023)Subodh Verma · Institute for Work & Health4 papers (2022–2023)Stefan D. Anker · Deutsches Herzzentrum München3 papers (2022–2023)Tomoko Iwata · Queen Elizabeth University Hospital3 papers (2022–2023)Michael Böhm · University of Stuttgart3 papers (2022–2023)Muhammad Shahzeb Khan · Temple College3 papers (2020–2023)Muhammad Usman · Chongqing University of Technology3 papers (2020–2023)Stephen J. Greene · Duke University2 papers (2022–2023)Mikhail Sumin · Duke University Hospital2 papers (2022–2025)Piotr Ponikowski · University of Business in Wrocław2 papers (2022–2023)Mikhail Kosiborod · Nagoya University2 papers (2021–2023)